Spots Global Cancer Trial Database for PeproStat Haemostat Study in Subjects Undergoing Liver Surgery
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PeproStat Haemostat Study in Subjects Undergoing Liver Surgery
Official Title: A Multi-centre, Open-label, Uncontrolled, First-in-Human Study to Evaluate the Safety and Tolerability and Explore the Efficacy of PeproStat in Gelita-Spon® Gelatin Sponge in Subjects Undergoing Open Liver Resection Surgery
Study ID: NCT02204930
Conditions
Interventions
Study Description
Brief Summary: The purpose of this First in Man study is to evaluate the safety and tolerability, as well as to explore efficacy of PeproStat, a new peptide based coagulant (haemostat), when used in patients undergoing open liver resection surgery.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Queen Elizabeth Hospital, Birmingham, , United Kingdom
Addenbrooke's University Hospital, Cambridge, , United Kingdom
Kings University Hospital, London, , United Kingdom
Derriford Hospital, Plymouth, , United Kingdom
Contact Details
Name: D Mirza, MBBS, MS, FRCS
Affiliation: The Queen Elizabeth Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
